Tauriga Sciences Inc. Now Registered as a Whole Foods Market Vendor
June 08 2020 - 10:23AM
InvestorsHub NewsWire
June 8, 2020 -- InvestorsHub NewsWire -- Tauriga Sciences, Inc.
(OTCQB:
TAUG) ("Tauriga" or the "Company"), a revenue generating,
diversified life sciences Company, with a proprietary line of
functional "supplement" chewing gums (versions: infused with CBD,
CBG, Vitamin C & Zinc) and edibles product(s) as well as two
ongoing Biotechnology initiatives, today announced that it is now a
Registered Whole Foods Market, Inc. ("Whole Foods") Vendor
("Supplier"). The Company's information has now been updated in the
Whole Foods Vendor Reporting Portal. On May 12, 2020, the Company
confirmed that it successfully increased its product liability
insurance coverage to $8,000,000 (an important step in enhancing
the Company's profile). The Company believes that its high quality
and diverse product(s) and product line(s) have the potential to
create successful - multi faceted - short, intermediate, and
long-term business model(s).
ABOUT TAURIGA SCIENCES INC.
Tauriga Sciences, Inc. (TAUG)
is a revenue generating, diversified life sciences company, engaged
in several major business activities and initiatives. The company
manufactures and distributes several proprietary retail products
and product lines, mainly focused on the Cannabidiol ("CBD") and
Cannabigerol ("CBG") Edibles market segment. The main product line,
branded as Tauri-Gum(TM), consists of a proprietary supplement
chewing gum that is both Kosher certified and Vegan formulated (CBD
Infused Tauri-Gum(TM) Flavors: Mint, Blood Orange, Pomegranate)
& (CBG Infused Tauri-Gum(TM) Flavors: Peach-Lemon and Black
Currant). The Company's commercialization strategy consists of a
broad array of retail customers, distributors, and a fast-growing
E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our
corporate website, for additional information, as well as
inquiries, at www.tauriga.com
Complementary to the Company's retail business, are its two
ongoing biotechnology initiatives. The first one relates to the
development of a Pharmaceutical grade version of Tauri-Gum(TM), for
nausea regulation (specifically designed to help patients that are
subjected to ongoing chemotherapy treatment). On March 18, 2020,
the Company announced that it filed a provisional U.S. patent
application covering its pharmaceutical grade version of
Tauri-Gum(TM). The Patent, filed with the U.S.P.T.O. is Titled
"MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS
OF TREATMENT". The second one relates to a collaboration agreement
with Aegea Biotechnologies Inc. for the co-development of a rapid,
multiplexed, Novel Coronavirus (COVID-19) test with superior
sensitivity and selectivity.
The Company is headquartered in New York City and operates a
regional office in Barcelona, Spain. In addition, the Company
operates a full time E-Commerce fulfillment center located in
LaGrangeville, New York.
DISCLAIMER -- Forward-Looking Statements
This press release contains certain "forward-looking statements"
as defined by the Private Securities Litigation Reform Act of 1995
which represent management's beliefs and assumptions concerning
future events. These forward-looking statements are often indicated
by using words such as "may," "will," "expects," "anticipates,"
believes, "hopes," "believes," or plans, and may include statements
regarding corporate objectives as well as the attainment of certain
corporate goals and milestones. Forward-looking statements are
based on present circumstances and on management's present beliefs
with respect to events that have not occurred, that may not occur,
or that may occur with different consequences or timing than those
now assumed or anticipated. Actual results may differ materially
from those expressed in forward looking statements due to known and
unknown risks and uncertainties, such as are not guarantees of
general economic and business conditions, the ability to
successfully develop and market products, consumer and business
consumption habits, the ability to consummate successful
acquisition and licensing transactions, fluctuations in exchange
rates, and other factors over which Tauriga has little or no
control. Many of these risks and uncertainties are discussed in
greater detail in the "Risk Factors" section of Tauriga's Form 10-K
and other filings made from time to time with the Securities and
Exchange Commission. Such forward-looking statements are made only
as of the date of this release, and Tauriga assumes no obligation
to update forward-looking statements to reflect subsequent events
or circumstances. You should not place undue reliance on these
forward-looking statements.
Contact:
CONTACT INFORMATION
Tauriga Sciences, Inc.
555 Madison Avenue, 5th Floor
New York, NY 10022
Chief Executive Officer
Mr. Seth M. Shaw
Email: sshaw@tauriga.com
cell # (917) 796 9926
Instagram: @taurigum
Twitter: @SethMShaw
Corp. Website: www.tauriga.com
E-Commerce Website: www.taurigum.com
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Apr 2023 to Apr 2024